Murray Ana Paula, Biscussi Brunella, Cavallaro Valeria, Donozo Martina, Rodriguez Silvana A
INQUISUR-CONICET, Departamento de Química, Universidad Nacional del Sur, Bahía Blanca, Argentina.
Curr Neuropharmacol. 2024;22(10):1621-1649. doi: 10.2174/1570159X21666230623105929.
Since the development of the "cholinergic hypothesis" as an important therapeutic approach in the treatment of Alzheimer's disease (AD), the scientific community has made a remarkable effort to discover new and effective molecules with the ability to inhibit the enzyme acetylcholinesterase (AChE). The natural function of this enzyme is to catalyze the hydrolysis of the neurotransmitter acetylcholine in the brain. Thus, its inhibition increases the levels of this neurochemical and improves the cholinergic functions in patients with AD alleviating the symptoms of this neurological disorder. In recent years, attention has also been focused on the role of another enzyme, butyrylcholinesterase (BChE), mainly in the advanced stages of AD, transforming this enzyme into another target of interest in the search for new anticholinesterase agents. Over the past decades, Nature has proven to be a rich source of bioactive compounds relevant to the discovery of new molecules with potential applications in AD therapy. Bioprospecting of new cholinesterase inhibitors among natural products has led to the discovery of an important number of new AChE and BChE inhibitors that became potential lead compounds for the development of anti-AD drugs. This review summarizes a total of 260 active compounds from 142 studies which correspond to the most relevant (IC ≤ 15 μM) research work published during 2012-2022 on plant-derived anticholinesterase compounds, as well as several potent inhibitors obtained from other sources like fungi, algae, and animals.
自从“胆碱能假说”作为治疗阿尔茨海默病(AD)的一种重要治疗方法发展以来,科学界做出了巨大努力来发现能够抑制乙酰胆碱酯酶(AChE)的新型有效分子。该酶的天然功能是催化大脑中神经递质乙酰胆碱的水解。因此,抑制该酶可提高这种神经化学物质的水平,并改善AD患者的胆碱能功能,减轻这种神经疾病的症状。近年来,另一种酶丁酰胆碱酯酶(BChE)的作用也受到关注,主要是在AD的晚期阶段,这使得该酶成为寻找新型抗胆碱酯酶药物的另一个感兴趣的靶点。在过去几十年中,自然界已被证明是生物活性化合物的丰富来源,这些化合物与发现可用于AD治疗的新分子相关。在天然产物中对新型胆碱酯酶抑制剂进行生物勘探,已发现大量新的AChE和BChE抑制剂,这些抑制剂成为开发抗AD药物的潜在先导化合物。本综述总结了来自142项研究的总共260种活性化合物,这些研究对应于2012年至2022年期间发表的关于植物源性抗胆碱酯酶化合物的最相关(IC≤15μM)研究工作,以及从真菌、藻类和动物等其他来源获得的几种强效抑制剂。